MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Prediction of turning characteristics parameters into Parkinson’s disease

    F. Khobkhun, A. Hirunkitti, T. Prasertsakul (Nakhon Pathom, Thailand)

    Objective: To investigate the parameters predicting turning dysfunction in individuals with Parkinson’s disease (PD). Background: Turning deficit in PD has significant implications particularly regarding increase…
  • 2023 International Congress

    Apolipoprotein E e4 genotype affects early motor progression in Parkinson’s disease through an effect on cognition

    M. Gevertzman, A. Hooyman, J. Longhurst, M. Landers (Las Vegas, USA)

    Objective: To evaluate the relationship between APOE e4 genotype, cognition, and motor progression in early Parkinson’s disease (PD). Background: The Apolipoprotein E (APOE) e4 genotype…
  • 2023 International Congress

    Chronic pain and the polytrauma clinical triad are risk factors for prodromal PD

    L. Neilson, N. Balba, J. Elliott, G. Scott, M. Heinricher, M. Lim (Portland, USA)

    Objective: This study aimed to assess whether chronic pain is a risk factor for prodromal Parkinson disease and determine if pain severity and comorbidity with…
  • 2023 International Congress

    Can a single-session of weight-shift training support people with Parkinson’s step from a freeze?

    Y. Russo, P. Leveridge, J. Ye, Z. Wang, M. Wilson, A. Nieuwboer, S. Lamb, E. Kal, M. Norris, W. Young (Exeter, United Kingdom)

    Objective: To assess the efficacy and the safety of a weight-shift (WS) intervention used in a complex and demanding gait context Background: Freezing of gait…
  • 2023 International Congress

    Drivers of longitudinal healthcare cost in Parkinson Disease

    S. Neo, SW. Goh, ES. Saffari, AB. Zhan, HL. Ng, W. Li, R. Hoe, Z. Xu, KY. Tay, WL. Au, LCS. Tan (Singapore, Singapore)

    Objective: To identify associations between baseline patient and disease characteristics, and longitudinal healthcare costs in Parkinson disease (PD). Background: Disease prevalence, disability-adjusted life-years, and PD…
  • 2023 International Congress

    Path To Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson’s Disease: Study Design

    C. Coffey, A. Siderowf, C. Tanner, K. Marek, M. Brumm, T. Simuni, P. Investigators, S. Chowdhury, T. Sherer, C. Kopil, K. Kieburtz, B. Saville, C. Allen-Savietta, B. Wendelberger, A. Crawford, K. Fabrizio ()

    Objective: To describe the study design and proposed timeline of the first interventional study in  biomarker defined prodromal Parkinson’s Disease (PD). Background: P2P is a…
  • 2023 International Congress

    Validation and replication of Parkinson disease behavioral subtypes

    C. Lessov-Schlaggar, P. Myers, J. Jackson, B. Maiti, P. Kotzbauer, J. Perlmutter, M. Campbell (St. Louis, USA)

    Objective: To validate and replicate clinical subtypes of Parkinson disease. Background: We recently identified three distinct clinical subtypes of Parkinson disease: motor (predominant motor with…
  • 2023 International Congress

    Pre-operative predominance of Tremor versus PIGD scores in drug OFF state predicts motor and non-motor outcomes of STN-DBS for Parkinson’s disease

    C. Nagireddy, K. Pillai, S. Joshua, A. Pnair, D. Panikar, M. Chacko, A. Kishore (Kochi, India)

    Objective: To test the predictive value of predominance of tremor versus PIGD scores on the motor and non-motor outcomes of bilateral STN DBS for Parkinson’s…
  • 2023 International Congress

    Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)

    L. Guedes, D. Hilt, M. Fonseca, I. Peixoto, H. Gama (Coronado, Portugal)

    Objective: To describe the safety profile and tolerability of BIA-28-6156 observed during phase 1 clinical trials. Background: BIA-28-6156 is a novel allosteric activator of beta-glucocerebrosidase…
  • 2023 International Congress

    Unveiling the Link between Stress-Related Disorders and Dysautonomic Symptoms in Parkinson’s Disease: A Cross-Sectional Study

    EJ. Acosta-Espinoza, IA. Ortiz-Marroquin, DI. Salinas-Leal, A. Salinas-Blancas, HM. Macias-Cruz, D. Martinez-Ramirez (Monterrey, Mexico)

    Objective: To explore the link between post-traumatic stress disorders and dysautonomic symptoms in Parkinson's disease. Background: Parkinson's disease is a complex condition that can lead…
  • « Previous Page
  • 1
  • …
  • 253
  • 254
  • 255
  • 256
  • 257
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley